Novavax, Inc. (NASDAQ:NVAX), a well-known clinical-stage vaccine company, focused on the development, discovery and commercialization of nanoparticle vaccines, announced changes to its senior leadership team. As per the reports, it has appointed Bob Darius as the new head of Global Quality Operations. Darius will take care of Quality Control, and Quality Assurance functions as part of this role.
With the change in his responsibilities, Darius will serve the company as a part of its senior management team.
Insights of Matter
Darius has been working tirelessly over the last 25 years in the fields of Quality Control, Quality Assurance, and Strategic Manufacturing. Before joining Novavax, he was associated as VP Quality Operations with GlaxoSmithKline for over a decade. As part of his role, Darius took care of company’s vaccine manufacturing business in Germany and North America. Not long ago, he also opted to head the Quality Advocacy Liaison of the enterprise.
In addition to the corporate experience, Darius also worked with Center for Biologics Evaluation and Research and Food and Drug Administration as a senior inspector and reviewer. He went to George Mason University for a Bachelor of Science degree in Biology. After his graduation, Darius took admission in the Johns Hopkins University for completing graduate work.
The entire senior management team of Novavax is delighted to have an experienced and skilled executive like Darius on the board. His product knowledge and subject-matter expertise will help Novavax forge ahead in the coming months. According to Stanley C. Erck, CEO & President, Novavax, it’s a delightful moment for the company.
It’s a crucial time for Novavax as it’s looking forward to implementing commercialization plans of RSV F Vaccine. Any wrong step at this point can harm its reputation badly. Darius comes with an abundance of experience and subject-matter knowledge of evolving quality and regulatory requirements, which will play a vital role in Novavax’s success in the long run.
